Key result
Lercanidipine is a third-generation calcium channel blocker with extensive evidence supporting its efficacy and safety in patients with hypertension, including those on combination therapy.
Why the study?
Does lercanidipine improve outcomes in patients with hypertension?
Does lercanidipine improve outcomes in patients with hypertension?
Lercanidipine is a third-generation calcium channel blocker with extensive evidence supporting its use and safety in patients with hypertension.
May support use in hypertension including combinations; confirms prior evidence but leaves outcome trials open.
Features and possibility of application of the calcium channel blocker lercanidipine in cardiology practice are discussed. The use of lercanidipine in patients with hypertension is supported by extensive evidences. The use of lercanidipine in certain categories of patients, including patients receiving combination therapy is also considered. The safety of lercanidipine in cardiac patients is discussed separately.
No takes yet. Share an insight, caveat, or question.
Емелина et al. (2015) conducted a review in hypertension. lercanidipine was evaluated. Lercanidipine is a third-generation calcium channel blocker with extensive evidence supporting its efficacy and safety in patients with hypertension, including those on combination therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: